Clinical trials
Breast Cancer Female clinical trials
Below are recruiting breast cancer female clinical trials, each written for real people, not researchers. We’re tracking 1,126 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07396324RecruitingPhase 2
A new drug before surgery for HR+ HER2- breast cancer
This trial tests whether the drug QL1706, given before surgery, can help treat hormone receptor positive and HER2-negative breast cancer. It is for people who have not yet had cancer spread to other parts of the body.
ShanghaiAges 18 years+ - NCT06225505Recruiting
Early detection of triple-negative breast cancer return
This trial uses blood tests to look for signs of cancer returning early in women who had triple-negative breast cancer. If caught early, doctors can start treatment sooner.
AvignonAges 18 years+ - NCT06130826RecruitingPhase 1
Immune therapy and radiation for advanced colorectal or breast cancer
This trial tests a combination of stereotactic body radiation therapy (SBRT) and an immune-boosting drug (M5A-IL2) for colorectal or breast cancer that has spread and is no longer responding to standard treatments. The goal is to activate your immune system to fight the cancer.
Duarte, CaliforniaAges 18 years+ - NCT03804944RecruitingPhase 2
Vaccine trial for hormone-positive breast cancer
This Phase 2 study tests an individualized vaccine made from your tumor information to help your immune system fight hormone-positive breast cancer. You may be able to participate if you meet specific hormone-receptor, health, and treatment-timing requirements.
Los Angeles, CaliforniaAges 18–90 - NCT03990896RecruitingPhase 2
Talazoparib for metastatic breast cancer with BRCA body DNA changes
This Phase 2 trial tests talazoparib, a targeted cancer medicine, in people with metastatic breast cancer that has a harmful BRCA1 or BRCA2 mutation found in tumor DNA circulating in the blood. If you qualify, the goal is to see how well this treatment works when the mutation is detected this specific way.
San Francisco, CaliforniaAges 18 years+ - NCT04265937Recruiting
Genetic screening for breast cancer risk in Chinese communities
This study checks certain genes using blood or mouth (oral) samples in people who already have breast cancer. The goal is to better understand genetic risk in Chinese communities and help guide future care.
Shanghai, Shanghai MunicipalityAges Any age - NCT04872166RecruitingPhase 1
BTX-A51 for advanced solid tumors and breast cancer patients
This Phase 1 study tests BTX-A51, an experimental treatment, in people with advanced cancers that can’t be cured with standard options. It mainly focuses on safety, side effects, and whether the drug can start helping certain tumors.
Lake Mary, FloridaAges 18 years+ - NCT05212454RecruitingPhase 3
Capecitabine added after surgery for high-risk ER-positive breast cancer
This Phase 3 study tests whether adding capecitabine (a chemotherapy pill) after breast cancer surgery can lower the chance the cancer comes back. It targets people with hormone-receptor–positive and HER2-negative breast cancer who are considered “high risk.”
Hanzhou, ZhejiangAges 18–70 - NCT05731258Recruiting
Watch how liposomal doxorubicin is used after breast cancer
This is an observational study that follows people receiving add-on (adjuvant) chemotherapy after primary breast cancer. It aims to understand treatment patterns and outcomes for patients healthy enough to receive liposomal doxorubicin and who have no major complications.
Hangzhou, ZhejiangAges 18–75 - NCT05744687RecruitingPhase 2/Phase 3
Letrozole plus SPH4336 versus letrozole alone for breast cancer
This study tests whether adding SPH4336 to letrozole works better than letrozole plus a placebo for treating hormone-receptor–positive, HER2-negative breast cancer in people starting first-line treatment. It may help slow cancer growth more effectively if the added drug is beneficial.
Fuzhou, FujianAges 18–75 - NCT05766410RecruitingPhase 2
Testing three CDK4/6 pills to change the immune response
This phase 2 trial compares ribociclib, palbociclib, and abemaciclib to see how each one affects your body’s immune response in estrogen- and/or progesterone-receptor–positive, HER2-negative early breast cancer. If you fit the stage and health requirements, joining could help doctors learn which treatment best “modulates” the immune system.
TaipeiAges 20 years+ - NCT05831397Recruiting
Study tests tiny blood “packages” during breast cancer chemotherapy
This trial studies small particles in the blood (called extracellular vesicles) in people receiving chemotherapy before surgery for breast cancer. It may help doctors learn more about what those particles can tell them during neoadjuvant treatment.
Pavia, LombardyAges 18–80 - NCT05891093RecruitingPhase 3
Fluzoparib plus hormone therapy after surgery for breast cancer
This Phase 3 trial tests whether fluzoparib added to standard hormone (endocrine) therapy after early breast cancer surgery can improve outcomes and safety. It may help patients whose tumors are ER-positive, HER2-negative, and a specific SNF3 subtype.
Beijing, Beijing MunicipalityAges 18–70 - NCT05989347RecruitingPhase 1
Dapagliflozin with chemo for breast cancer
This trial tests whether adding the drug dapagliflozin (a pill that lowers blood sugar) to standard chemotherapy before breast cancer surgery can improve outcomes. It is for women with high insulin levels and a higher BMI who are about to start chemotherapy.
New Haven, ConnecticutAges 18 years+ - NCT06171360Recruiting
Gut bacteria and CDK4/6 inhibitor treatment in breast cancer
This study looks at how gut bacteria affect response to a type of targeted therapy (CDK4/6 inhibitors) combined with hormone therapy in breast cancer that is hormone receptor-positive and HER2-negative. It may help find out why some people respond better to treatment and could lead to better personalized care.
BrusselsAges 18–100 - NCT06349512Recruiting
PET scan to predict treatment response in triple-negative breast cancer
This trial uses a special PET scan (68Ga-FAPI-46) to see if it can predict how well chemotherapy plus immunotherapy (pembrolizumab) works in people with triple-negative breast cancer before surgery. It aims to help doctors understand if the treatment is effective earlier.
AntonyAges 18 years+ - NCT06387628RecruitingPhase 2
LM-108 with immunotherapy for advanced triple-negative breast cancer
This trial tests a new drug called LM-108 combined with a PD-1 inhibitor (a type of immunotherapy) for people with triple-negative breast cancer that has come back or spread. It aims to see if this combination can help shrink tumors or slow the disease.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06493864RecruitingPhase 1
BL-B16D1 for advanced breast cancer and solid tumors
This trial tests a new drug called BL-B16D1 for people with advanced breast cancer or other solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and how well it works.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06503783RecruitingPhase 1
Study of BL-M17D1 for advanced breast cancer and solid tumors
This trial tests a new drug, BL-M17D1, for people with advanced breast cancer (HER2 positive or negative) or other solid tumors that have spread. It aims to see if the drug is safe and effective.
Harbin, HeilongjiangAges 18–75 - NCT06560385Recruiting
Probiotics for hair loss in breast cancer patients
This study tests whether a special mix of probiotics (good bacteria) can help prevent or reduce hair loss caused by chemotherapy for breast cancer. You would take the probiotic powder every day during chemotherapy.
Hong KongAges 18–60 - NCT06586047RecruitingEarly Phase 1
PSMA PET scan for triple-negative breast cancer
This trial uses a special PET scan to see if PSMA, a protein on some cancer cells, can help detect triple-negative breast cancer that has spread to other parts of the body.
Iowa City, IowaAges 18–90 - NCT06609187RecruitingPhase 1
Study of GNC-077 for advanced breast cancer and other solid tumors
This trial tests a new drug called GNC-077 for people with advanced breast cancer or other solid tumors that have spread. It aims to see if the drug is safe and effective.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06851299RecruitingPhase 2
Trop2-ADC alone or with immunotherapy for advanced triple-negative breast cancer
This study tests a new drug called Trop2-ADC, either alone or combined with immunotherapy, for people with advanced triple-negative breast cancer. The goal is to see if it can shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18–70 - NCT06892093Recruiting
Probiotics to prevent diarrhea from neratinib in breast cancer
This trial tests whether taking probiotics can help prevent diarrhea caused by the breast cancer drug neratinib. If you are a woman with HER2-positive breast cancer and are about to start neratinib, this study may help manage a common side effect.
Guangzhou, GuangdongAges 18 years+
Hear when a new Breast Cancer Female trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer female?
- Yes. Clin2 currently lists 1,126 recruiting breast cancer female studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer female trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer female trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.